Global Peptide Cancer Vaccine Market Analysis and Forecast 2024-2030
Summary
Cancer peptide vaccination, as an immunotherapeutic approach against solid tumors, is currently employed in several clinical research protocols. The underlying mechanism of peptide-based vaccines involves the generation of a T-cell immune response against tumor or enhancement of an endogenous antitumor immunity pre-existing in the host.
According to APO Research, The global Peptide Cancer Vaccine market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Peptide Cancer Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Asia-Pacific market for Peptide Cancer Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for Peptide Cancer Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Europe market for Peptide Cancer Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The major global manufacturers of Peptide Cancer Vaccine include Boston Biomedical, Ultimovacs, BrightPath Biotherapeutics, TapImmune, Immatics, Sellas, Imugene, VAXON Biotech and Generex Biotechnology, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Peptide Cancer Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Peptide Cancer Vaccine, also provides the sales of main regions and countries. Of the upcoming market potential for Peptide Cancer Vaccine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Peptide Cancer Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Peptide Cancer Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for Peptide Cancer Vaccine sales, projected growth trends, production technology, application and end-user industry.
Peptide Cancer Vaccine segment by Company
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide Cancer Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Peptide Cancer Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide Cancer Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Sales (consumption), revenue of Peptide Cancer Vaccine in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 4: Detailed analysis of Peptide Cancer Vaccine manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Peptide Cancer Vaccine sales, revenue, price, gross margin, and recent development, etc.
Chapter 8: North America (US & Canada) by type, by application and by country, sales, and revenue for each segment.
Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.
Chapter 10: China type, by application, sales, and revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.
Chapter 12: Middle East, Africa, and Latin America type, by application and by country, sales, and revenue for each segment.
Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 14: The main concluding insights of the report.
Cancer peptide vaccination, as an immunotherapeutic approach against solid tumors, is currently employed in several clinical research protocols. The underlying mechanism of peptide-based vaccines involves the generation of a T-cell immune response against tumor or enhancement of an endogenous antitumor immunity pre-existing in the host.
According to APO Research, The global Peptide Cancer Vaccine market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Peptide Cancer Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Asia-Pacific market for Peptide Cancer Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for Peptide Cancer Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Europe market for Peptide Cancer Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The major global manufacturers of Peptide Cancer Vaccine include Boston Biomedical, Ultimovacs, BrightPath Biotherapeutics, TapImmune, Immatics, Sellas, Imugene, VAXON Biotech and Generex Biotechnology, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Peptide Cancer Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Peptide Cancer Vaccine, also provides the sales of main regions and countries. Of the upcoming market potential for Peptide Cancer Vaccine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Peptide Cancer Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Peptide Cancer Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for Peptide Cancer Vaccine sales, projected growth trends, production technology, application and end-user industry.
Peptide Cancer Vaccine segment by Company
- Boston Biomedical
- Ultimovacs
- BrightPath Biotherapeutics
- TapImmune
- Immatics
- Sellas
- Imugene
- VAXON Biotech
- Generex Biotechnology
- ISA Pharmaceuticals
- OncoTherapy Science
- ITK-1
- GRN-1201
- TPIV200
- TPIV110
- UV1
- Galinpepimut-S
- TARP 27-35
- HER-Vaxx
- Vx-001
- Others
- Breast Cancer
- Lung Cancer
- Melanoma
- Prostate Cancer
- Others
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia
- China Taiwan
- Indonesia
- Thailand
- Malaysia
- Latin America
- Mexico
- Brazil
- Argentina
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide Cancer Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Peptide Cancer Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide Cancer Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Sales (consumption), revenue of Peptide Cancer Vaccine in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 4: Detailed analysis of Peptide Cancer Vaccine manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Peptide Cancer Vaccine sales, revenue, price, gross margin, and recent development, etc.
Chapter 8: North America (US & Canada) by type, by application and by country, sales, and revenue for each segment.
Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.
Chapter 10: China type, by application, sales, and revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.
Chapter 12: Middle East, Africa, and Latin America type, by application and by country, sales, and revenue for each segment.
Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 14: The main concluding insights of the report.
1 MARKET OVERVIEW
1.1 Product Definition
1.2 Peptide Cancer Vaccine Market by Pipeline
1.2.1 Global Peptide Cancer Vaccine Market Size by Pipeline, 2019 VS 2023 VS 2030
1.2.2 ITK-1
1.2.3 GRN-1201
1.2.4 TPIV200
1.2.5 TPIV110
1.2.6 UV1
1.2.7 Galinpepimut-S
1.2.8 TARP 27-35
1.2.9 HER-Vaxx
1.2.10 Vx-001
1.2.11 Others
1.3 Peptide Cancer Vaccine Market by Application
1.3.1 Global Peptide Cancer Vaccine Market Size by Application, 2019 VS 2023 VS 2030
1.3.2 Breast Cancer
1.3.3 Lung Cancer
1.3.4 Melanoma
1.3.5 Prostate Cancer
1.3.6 Others
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 PEPTIDE CANCER VACCINE MARKET DYNAMICS
2.1 Peptide Cancer Vaccine Industry Trends
2.2 Peptide Cancer Vaccine Industry Drivers
2.3 Peptide Cancer Vaccine Industry Opportunities and Challenges
2.4 Peptide Cancer Vaccine Industry Restraints
3 GLOBAL MARKET GROWTH PROSPECTS
3.1 Global Peptide Cancer Vaccine Revenue Estimates and Forecasts (2019-2030)
3.2 Global Peptide Cancer Vaccine Revenue by Region
3.2.1 Global Peptide Cancer Vaccine Revenue by Region: 2019 VS 2023 VS 2030
3.2.2 Global Peptide Cancer Vaccine Revenue by Region (2019-2024)
3.2.3 Global Peptide Cancer Vaccine Revenue by Region (2025-2030)
3.2.4 Global Peptide Cancer Vaccine Revenue Market Share by Region (2019-2030)
3.3 Global Peptide Cancer Vaccine Sales Estimates and Forecasts 2019-2030
3.4 Global Peptide Cancer Vaccine Sales by Region
3.4.1 Global Peptide Cancer Vaccine Sales by Region: 2019 VS 2023 VS 2030
3.4.2 Global Peptide Cancer Vaccine Sales by Region (2019-2024)
3.4.3 Global Peptide Cancer Vaccine Sales by Region (2025-2030)
3.4.4 Global Peptide Cancer Vaccine Sales Market Share by Region (2019-2030)
3.5 US & Canada
3.6 Europe
3.7 China
3.8 Asia (Excluding China)
3.9 Middle East, Africa and Latin America
4 MARKET COMPETITIVE LANDSCAPE BY MANUFACTURERS
4.1 Global Peptide Cancer Vaccine Revenue by Manufacturers
4.1.1 Global Peptide Cancer Vaccine Revenue by Manufacturers (2019-2024)
4.1.2 Global Peptide Cancer Vaccine Revenue Market Share by Manufacturers (2019-2024)
4.1.3 Global Peptide Cancer Vaccine Manufacturers Revenue Share Top 10 and Top 5 in 2023
4.2 Global Peptide Cancer Vaccine Sales by Manufacturers
4.2.1 Global Peptide Cancer Vaccine Sales by Manufacturers (2019-2024)
4.2.2 Global Peptide Cancer Vaccine Sales Market Share by Manufacturers (2019-2024)
4.2.3 Global Peptide Cancer Vaccine Manufacturers Sales Share Top 10 and Top 5 in 2023
4.3 Global Peptide Cancer Vaccine Sales Price by Manufacturers (2019-2024)
4.4 Global Peptide Cancer Vaccine Key Manufacturers Ranking, 2022 VS 2023 VS 2024
4.5 Global Peptide Cancer Vaccine Key Manufacturers Manufacturing Sites & Headquarters
4.6 Global Peptide Cancer Vaccine Manufacturers, Product Type & Application
4.7 Global Peptide Cancer Vaccine Manufacturers Commercialization Time
4.8 Market Competitive Analysis
4.8.1 Global Peptide Cancer Vaccine Market CR5 and HHI
4.8.2 2023 Peptide Cancer Vaccine Tier 1, Tier 2, and Tier
5 PEPTIDE CANCER VACCINE MARKET BY TYPE
5.1 Global Peptide Cancer Vaccine Revenue by Type
5.1.1 Global Peptide Cancer Vaccine Revenue by Type (2019 VS 2023 VS 2030)
5.1.2 Global Peptide Cancer Vaccine Revenue by Type (2019-2030) & (US$ Million)
5.1.3 Global Peptide Cancer Vaccine Revenue Market Share by Type (2019-2030)
5.2 Global Peptide Cancer Vaccine Sales by Type
5.2.1 Global Peptide Cancer Vaccine Sales by Type (2019 VS 2023 VS 2030)
5.2.2 Global Peptide Cancer Vaccine Sales by Type (2019-2030) & (K Doses)
5.2.3 Global Peptide Cancer Vaccine Sales Market Share by Type (2019-2030)
5.3 Global Peptide Cancer Vaccine Price by Type
6 PEPTIDE CANCER VACCINE MARKET BY APPLICATION
6.1 Global Peptide Cancer Vaccine Revenue by Application
6.1.1 Global Peptide Cancer Vaccine Revenue by Application (2019 VS 2023 VS 2030)
6.1.2 Global Peptide Cancer Vaccine Revenue by Application (2019-2030) & (US$ Million)
6.1.3 Global Peptide Cancer Vaccine Revenue Market Share by Application (2019-2030)
6.2 Global Peptide Cancer Vaccine Sales by Application
6.2.1 Global Peptide Cancer Vaccine Sales by Application (2019 VS 2023 VS 2030)
6.2.2 Global Peptide Cancer Vaccine Sales by Application (2019-2030) & (K Doses)
6.2.3 Global Peptide Cancer Vaccine Sales Market Share by Application (2019-2030)
6.3 Global Peptide Cancer Vaccine Price by Application
7 COMPANY PROFILES
7.1 Boston Biomedical
7.1.1 Boston Biomedical Comapny Information
7.1.2 Boston Biomedical Business Overview
7.1.3 Boston Biomedical Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
7.1.4 Boston Biomedical Peptide Cancer Vaccine Product Portfolio
7.1.5 Boston Biomedical Recent Developments
7.2 Ultimovacs
7.2.1 Ultimovacs Comapny Information
7.2.2 Ultimovacs Business Overview
7.2.3 Ultimovacs Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
7.2.4 Ultimovacs Peptide Cancer Vaccine Product Portfolio
7.2.5 Ultimovacs Recent Developments
7.3 BrightPath Biotherapeutics
7.3.1 BrightPath Biotherapeutics Comapny Information
7.3.2 BrightPath Biotherapeutics Business Overview
7.3.3 BrightPath Biotherapeutics Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
7.3.4 BrightPath Biotherapeutics Peptide Cancer Vaccine Product Portfolio
7.3.5 BrightPath Biotherapeutics Recent Developments
7.4 TapImmune
7.4.1 TapImmune Comapny Information
7.4.2 TapImmune Business Overview
7.4.3 TapImmune Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
7.4.4 TapImmune Peptide Cancer Vaccine Product Portfolio
7.4.5 TapImmune Recent Developments
7.5 Immatics
7.5.1 Immatics Comapny Information
7.5.2 Immatics Business Overview
7.5.3 Immatics Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
7.5.4 Immatics Peptide Cancer Vaccine Product Portfolio
7.5.5 Immatics Recent Developments
7.6 Sellas
7.6.1 Sellas Comapny Information
7.6.2 Sellas Business Overview
7.6.3 Sellas Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
7.6.4 Sellas Peptide Cancer Vaccine Product Portfolio
7.6.5 Sellas Recent Developments
7.7 Imugene
7.7.1 Imugene Comapny Information
7.7.2 Imugene Business Overview
7.7.3 Imugene Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
7.7.4 Imugene Peptide Cancer Vaccine Product Portfolio
7.7.5 Imugene Recent Developments
7.8 VAXON Biotech
7.8.1 VAXON Biotech Comapny Information
7.8.2 VAXON Biotech Business Overview
7.8.3 VAXON Biotech Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
7.8.4 VAXON Biotech Peptide Cancer Vaccine Product Portfolio
7.8.5 VAXON Biotech Recent Developments
7.9 Generex Biotechnology
7.9.1 Generex Biotechnology Comapny Information
7.9.2 Generex Biotechnology Business Overview
7.9.3 Generex Biotechnology Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
7.9.4 Generex Biotechnology Peptide Cancer Vaccine Product Portfolio
7.9.5 Generex Biotechnology Recent Developments
7.10 ISA Pharmaceuticals
7.10.1 ISA Pharmaceuticals Comapny Information
7.10.2 ISA Pharmaceuticals Business Overview
7.10.3 ISA Pharmaceuticals Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
7.10.4 ISA Pharmaceuticals Peptide Cancer Vaccine Product Portfolio
7.10.5 ISA Pharmaceuticals Recent Developments
7.11 OncoTherapy Science
7.11.1 OncoTherapy Science Comapny Information
7.11.2 OncoTherapy Science Business Overview
7.11.3 OncoTherapy Science Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
7.11.4 OncoTherapy Science Peptide Cancer Vaccine Product Portfolio
7.11.5 OncoTherapy Science Recent Developments
8 NORTH AMERICA
8.1 North America Peptide Cancer Vaccine Market Size by Pipeline
8.1.1 North America Peptide Cancer Vaccine Revenue by Pipeline (2019-2030)
8.1.2 North America Peptide Cancer Vaccine Sales by Pipeline (2019-2030)
8.1.3 North America Peptide Cancer Vaccine Price by Pipeline (2019-2030)
8.2 North America Peptide Cancer Vaccine Market Size by Application
8.2.1 North America Peptide Cancer Vaccine Revenue by Application (2019-2030)
8.2.2 North America Peptide Cancer Vaccine Sales by Application (2019-2030)
8.2.3 North America Peptide Cancer Vaccine Price by Application (2019-2030)
8.3 North America Peptide Cancer Vaccine Market Size by Country
8.3.1 North America Peptide Cancer Vaccine Revenue Grow Rate by Country (2019 VS 2023 VS 2030)
8.3.2 North America Peptide Cancer Vaccine Sales by Country (2019 VS 2023 VS 2030)
8.3.3 North America Peptide Cancer Vaccine Price by Country (2019-2030)
8.3.4 U.S.
8.3.5 Canada
9 EUROPE
9.1 Europe Peptide Cancer Vaccine Market Size by Pipeline
9.1.1 Europe Peptide Cancer Vaccine Revenue by Pipeline (2019-2030)
9.1.2 Europe Peptide Cancer Vaccine Sales by Pipeline (2019-2030)
9.1.3 Europe Peptide Cancer Vaccine Price by Pipeline (2019-2030)
9.2 Europe Peptide Cancer Vaccine Market Size by Application
9.2.1 Europe Peptide Cancer Vaccine Revenue by Application (2019-2030)
9.2.2 Europe Peptide Cancer Vaccine Sales by Application (2019-2030)
9.2.3 Europe Peptide Cancer Vaccine Price by Application (2019-2030)
9.3 Europe Peptide Cancer Vaccine Market Size by Country
9.3.1 Europe Peptide Cancer Vaccine Revenue Grow Rate by Country (2019 VS 2023 VS 2030)
9.3.2 Europe Peptide Cancer Vaccine Sales by Country (2019 VS 2023 VS 2030)
9.3.3 Europe Peptide Cancer Vaccine Price by Country (2019-2030)
9.3.4 Germany
9.3.5 France
9.3.6 U.K.
9.3.7 Italy
9.3.8 Russia
10 CHINA
10.1 China Peptide Cancer Vaccine Market Size by Pipeline
10.1.1 China Peptide Cancer Vaccine Revenue by Pipeline (2019-2030)
10.1.2 China Peptide Cancer Vaccine Sales by Pipeline (2019-2030)
10.1.3 China Peptide Cancer Vaccine Price by Pipeline (2019-2030)
10.2 China Peptide Cancer Vaccine Market Size by Application
10.2.1 China Peptide Cancer Vaccine Revenue by Application (2019-2030)
10.2.2 China Peptide Cancer Vaccine Sales by Application (2019-2030)
10.2.3 China Peptide Cancer Vaccine Price by Application (2019-2030)
11 ASIA (EXCLUDING CHINA)
11.1 Asia Peptide Cancer Vaccine Market Size by Pipeline
11.1.1 Asia Peptide Cancer Vaccine Revenue by Pipeline (2019-2030)
11.1.2 Asia Peptide Cancer Vaccine Sales by Pipeline (2019-2030)
11.1.3 Asia Peptide Cancer Vaccine Price by Pipeline (2019-2030)
11.2 Asia Peptide Cancer Vaccine Market Size by Application
11.2.1 Asia Peptide Cancer Vaccine Revenue by Application (2019-2030)
11.2.2 Asia Peptide Cancer Vaccine Sales by Application (2019-2030)
11.2.3 Asia Peptide Cancer Vaccine Price by Application (2019-2030)
11.3 Asia Peptide Cancer Vaccine Market Size by Country
11.3.1 Asia Peptide Cancer Vaccine Revenue Grow Rate by Country (2019 VS 2023 VS 2030)
11.3.2 Asia Peptide Cancer Vaccine Sales by Country (2019 VS 2023 VS 2030)
11.3.3 Asia Peptide Cancer Vaccine Price by Country (2019-2030)
11.3.4 Japan
11.3.5 South Korea
11.3.6 India
11.3.7 Australia
11.3.8 China Taiwan
11.3.9 Southeast Asia
12 MIDDLE EAST, AFRICA AND LATIN AMERICA
12.1 MEALA Peptide Cancer Vaccine Market Size by Pipeline
12.1.1 MEALA Peptide Cancer Vaccine Revenue by Pipeline (2019-2030)
12.1.2 MEALA Peptide Cancer Vaccine Sales by Pipeline (2019-2030)
12.1.3 MEALA Peptide Cancer Vaccine Price by Pipeline (2019-2030)
12.2 MEALA Peptide Cancer Vaccine Market Size by Application
12.2.1 MEALA Peptide Cancer Vaccine Revenue by Application (2019-2030)
12.2.2 MEALA Peptide Cancer Vaccine Sales by Application (2019-2030)
12.2.3 MEALA Peptide Cancer Vaccine Price by Application (2019-2030)
12.3 MEALA Peptide Cancer Vaccine Market Size by Country
12.3.1 MEALA Peptide Cancer Vaccine Revenue Grow Rate by Country (2019 VS 2023 VS 2030)
12.3.2 MEALA Peptide Cancer Vaccine Sales by Country (2019 VS 2023 VS 2030)
12.3.3 MEALA Peptide Cancer Vaccine Price by Country (2019-2030)
12.3.4 Mexico
12.3.5 Brazil
12.3.6 Israel
12.3.7 Argentina
12.3.8 Colombia
12.3.9 Turkey
12.3.10 Saudi Arabia
12.3.11 UAE
13 VALUE CHAIN AND SALES CHANNELS ANALYSIS
13.1 Peptide Cancer Vaccine Value Chain Analysis
13.1.1 Peptide Cancer Vaccine Key Raw Materials
13.1.2 Raw Materials Key Suppliers
13.1.3 Manufacturing Cost Structure
13.1.4 Peptide Cancer Vaccine Production Mode & Process
13.2 Peptide Cancer Vaccine Sales Channels Analysis
13.2.1 Direct Comparison with Distribution Share
13.2.2 Peptide Cancer Vaccine Distributors
13.2.3 Peptide Cancer Vaccine Customers
14 CONCLUDING INSIGHTS
15 APPENDIX
15.1 Reasons for Doing This Study
15.2 Research Methodology
15.3 Research Process
15.4 Authors List of This Report
15.5 Data Source
15.5.1 Secondary Sources
15.5.2 Primary Sources
15.6 Disclaimer
1.1 Product Definition
1.2 Peptide Cancer Vaccine Market by Pipeline
1.2.1 Global Peptide Cancer Vaccine Market Size by Pipeline, 2019 VS 2023 VS 2030
1.2.2 ITK-1
1.2.3 GRN-1201
1.2.4 TPIV200
1.2.5 TPIV110
1.2.6 UV1
1.2.7 Galinpepimut-S
1.2.8 TARP 27-35
1.2.9 HER-Vaxx
1.2.10 Vx-001
1.2.11 Others
1.3 Peptide Cancer Vaccine Market by Application
1.3.1 Global Peptide Cancer Vaccine Market Size by Application, 2019 VS 2023 VS 2030
1.3.2 Breast Cancer
1.3.3 Lung Cancer
1.3.4 Melanoma
1.3.5 Prostate Cancer
1.3.6 Others
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 PEPTIDE CANCER VACCINE MARKET DYNAMICS
2.1 Peptide Cancer Vaccine Industry Trends
2.2 Peptide Cancer Vaccine Industry Drivers
2.3 Peptide Cancer Vaccine Industry Opportunities and Challenges
2.4 Peptide Cancer Vaccine Industry Restraints
3 GLOBAL MARKET GROWTH PROSPECTS
3.1 Global Peptide Cancer Vaccine Revenue Estimates and Forecasts (2019-2030)
3.2 Global Peptide Cancer Vaccine Revenue by Region
3.2.1 Global Peptide Cancer Vaccine Revenue by Region: 2019 VS 2023 VS 2030
3.2.2 Global Peptide Cancer Vaccine Revenue by Region (2019-2024)
3.2.3 Global Peptide Cancer Vaccine Revenue by Region (2025-2030)
3.2.4 Global Peptide Cancer Vaccine Revenue Market Share by Region (2019-2030)
3.3 Global Peptide Cancer Vaccine Sales Estimates and Forecasts 2019-2030
3.4 Global Peptide Cancer Vaccine Sales by Region
3.4.1 Global Peptide Cancer Vaccine Sales by Region: 2019 VS 2023 VS 2030
3.4.2 Global Peptide Cancer Vaccine Sales by Region (2019-2024)
3.4.3 Global Peptide Cancer Vaccine Sales by Region (2025-2030)
3.4.4 Global Peptide Cancer Vaccine Sales Market Share by Region (2019-2030)
3.5 US & Canada
3.6 Europe
3.7 China
3.8 Asia (Excluding China)
3.9 Middle East, Africa and Latin America
4 MARKET COMPETITIVE LANDSCAPE BY MANUFACTURERS
4.1 Global Peptide Cancer Vaccine Revenue by Manufacturers
4.1.1 Global Peptide Cancer Vaccine Revenue by Manufacturers (2019-2024)
4.1.2 Global Peptide Cancer Vaccine Revenue Market Share by Manufacturers (2019-2024)
4.1.3 Global Peptide Cancer Vaccine Manufacturers Revenue Share Top 10 and Top 5 in 2023
4.2 Global Peptide Cancer Vaccine Sales by Manufacturers
4.2.1 Global Peptide Cancer Vaccine Sales by Manufacturers (2019-2024)
4.2.2 Global Peptide Cancer Vaccine Sales Market Share by Manufacturers (2019-2024)
4.2.3 Global Peptide Cancer Vaccine Manufacturers Sales Share Top 10 and Top 5 in 2023
4.3 Global Peptide Cancer Vaccine Sales Price by Manufacturers (2019-2024)
4.4 Global Peptide Cancer Vaccine Key Manufacturers Ranking, 2022 VS 2023 VS 2024
4.5 Global Peptide Cancer Vaccine Key Manufacturers Manufacturing Sites & Headquarters
4.6 Global Peptide Cancer Vaccine Manufacturers, Product Type & Application
4.7 Global Peptide Cancer Vaccine Manufacturers Commercialization Time
4.8 Market Competitive Analysis
4.8.1 Global Peptide Cancer Vaccine Market CR5 and HHI
4.8.2 2023 Peptide Cancer Vaccine Tier 1, Tier 2, and Tier
5 PEPTIDE CANCER VACCINE MARKET BY TYPE
5.1 Global Peptide Cancer Vaccine Revenue by Type
5.1.1 Global Peptide Cancer Vaccine Revenue by Type (2019 VS 2023 VS 2030)
5.1.2 Global Peptide Cancer Vaccine Revenue by Type (2019-2030) & (US$ Million)
5.1.3 Global Peptide Cancer Vaccine Revenue Market Share by Type (2019-2030)
5.2 Global Peptide Cancer Vaccine Sales by Type
5.2.1 Global Peptide Cancer Vaccine Sales by Type (2019 VS 2023 VS 2030)
5.2.2 Global Peptide Cancer Vaccine Sales by Type (2019-2030) & (K Doses)
5.2.3 Global Peptide Cancer Vaccine Sales Market Share by Type (2019-2030)
5.3 Global Peptide Cancer Vaccine Price by Type
6 PEPTIDE CANCER VACCINE MARKET BY APPLICATION
6.1 Global Peptide Cancer Vaccine Revenue by Application
6.1.1 Global Peptide Cancer Vaccine Revenue by Application (2019 VS 2023 VS 2030)
6.1.2 Global Peptide Cancer Vaccine Revenue by Application (2019-2030) & (US$ Million)
6.1.3 Global Peptide Cancer Vaccine Revenue Market Share by Application (2019-2030)
6.2 Global Peptide Cancer Vaccine Sales by Application
6.2.1 Global Peptide Cancer Vaccine Sales by Application (2019 VS 2023 VS 2030)
6.2.2 Global Peptide Cancer Vaccine Sales by Application (2019-2030) & (K Doses)
6.2.3 Global Peptide Cancer Vaccine Sales Market Share by Application (2019-2030)
6.3 Global Peptide Cancer Vaccine Price by Application
7 COMPANY PROFILES
7.1 Boston Biomedical
7.1.1 Boston Biomedical Comapny Information
7.1.2 Boston Biomedical Business Overview
7.1.3 Boston Biomedical Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
7.1.4 Boston Biomedical Peptide Cancer Vaccine Product Portfolio
7.1.5 Boston Biomedical Recent Developments
7.2 Ultimovacs
7.2.1 Ultimovacs Comapny Information
7.2.2 Ultimovacs Business Overview
7.2.3 Ultimovacs Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
7.2.4 Ultimovacs Peptide Cancer Vaccine Product Portfolio
7.2.5 Ultimovacs Recent Developments
7.3 BrightPath Biotherapeutics
7.3.1 BrightPath Biotherapeutics Comapny Information
7.3.2 BrightPath Biotherapeutics Business Overview
7.3.3 BrightPath Biotherapeutics Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
7.3.4 BrightPath Biotherapeutics Peptide Cancer Vaccine Product Portfolio
7.3.5 BrightPath Biotherapeutics Recent Developments
7.4 TapImmune
7.4.1 TapImmune Comapny Information
7.4.2 TapImmune Business Overview
7.4.3 TapImmune Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
7.4.4 TapImmune Peptide Cancer Vaccine Product Portfolio
7.4.5 TapImmune Recent Developments
7.5 Immatics
7.5.1 Immatics Comapny Information
7.5.2 Immatics Business Overview
7.5.3 Immatics Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
7.5.4 Immatics Peptide Cancer Vaccine Product Portfolio
7.5.5 Immatics Recent Developments
7.6 Sellas
7.6.1 Sellas Comapny Information
7.6.2 Sellas Business Overview
7.6.3 Sellas Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
7.6.4 Sellas Peptide Cancer Vaccine Product Portfolio
7.6.5 Sellas Recent Developments
7.7 Imugene
7.7.1 Imugene Comapny Information
7.7.2 Imugene Business Overview
7.7.3 Imugene Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
7.7.4 Imugene Peptide Cancer Vaccine Product Portfolio
7.7.5 Imugene Recent Developments
7.8 VAXON Biotech
7.8.1 VAXON Biotech Comapny Information
7.8.2 VAXON Biotech Business Overview
7.8.3 VAXON Biotech Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
7.8.4 VAXON Biotech Peptide Cancer Vaccine Product Portfolio
7.8.5 VAXON Biotech Recent Developments
7.9 Generex Biotechnology
7.9.1 Generex Biotechnology Comapny Information
7.9.2 Generex Biotechnology Business Overview
7.9.3 Generex Biotechnology Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
7.9.4 Generex Biotechnology Peptide Cancer Vaccine Product Portfolio
7.9.5 Generex Biotechnology Recent Developments
7.10 ISA Pharmaceuticals
7.10.1 ISA Pharmaceuticals Comapny Information
7.10.2 ISA Pharmaceuticals Business Overview
7.10.3 ISA Pharmaceuticals Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
7.10.4 ISA Pharmaceuticals Peptide Cancer Vaccine Product Portfolio
7.10.5 ISA Pharmaceuticals Recent Developments
7.11 OncoTherapy Science
7.11.1 OncoTherapy Science Comapny Information
7.11.2 OncoTherapy Science Business Overview
7.11.3 OncoTherapy Science Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
7.11.4 OncoTherapy Science Peptide Cancer Vaccine Product Portfolio
7.11.5 OncoTherapy Science Recent Developments
8 NORTH AMERICA
8.1 North America Peptide Cancer Vaccine Market Size by Pipeline
8.1.1 North America Peptide Cancer Vaccine Revenue by Pipeline (2019-2030)
8.1.2 North America Peptide Cancer Vaccine Sales by Pipeline (2019-2030)
8.1.3 North America Peptide Cancer Vaccine Price by Pipeline (2019-2030)
8.2 North America Peptide Cancer Vaccine Market Size by Application
8.2.1 North America Peptide Cancer Vaccine Revenue by Application (2019-2030)
8.2.2 North America Peptide Cancer Vaccine Sales by Application (2019-2030)
8.2.3 North America Peptide Cancer Vaccine Price by Application (2019-2030)
8.3 North America Peptide Cancer Vaccine Market Size by Country
8.3.1 North America Peptide Cancer Vaccine Revenue Grow Rate by Country (2019 VS 2023 VS 2030)
8.3.2 North America Peptide Cancer Vaccine Sales by Country (2019 VS 2023 VS 2030)
8.3.3 North America Peptide Cancer Vaccine Price by Country (2019-2030)
8.3.4 U.S.
8.3.5 Canada
9 EUROPE
9.1 Europe Peptide Cancer Vaccine Market Size by Pipeline
9.1.1 Europe Peptide Cancer Vaccine Revenue by Pipeline (2019-2030)
9.1.2 Europe Peptide Cancer Vaccine Sales by Pipeline (2019-2030)
9.1.3 Europe Peptide Cancer Vaccine Price by Pipeline (2019-2030)
9.2 Europe Peptide Cancer Vaccine Market Size by Application
9.2.1 Europe Peptide Cancer Vaccine Revenue by Application (2019-2030)
9.2.2 Europe Peptide Cancer Vaccine Sales by Application (2019-2030)
9.2.3 Europe Peptide Cancer Vaccine Price by Application (2019-2030)
9.3 Europe Peptide Cancer Vaccine Market Size by Country
9.3.1 Europe Peptide Cancer Vaccine Revenue Grow Rate by Country (2019 VS 2023 VS 2030)
9.3.2 Europe Peptide Cancer Vaccine Sales by Country (2019 VS 2023 VS 2030)
9.3.3 Europe Peptide Cancer Vaccine Price by Country (2019-2030)
9.3.4 Germany
9.3.5 France
9.3.6 U.K.
9.3.7 Italy
9.3.8 Russia
10 CHINA
10.1 China Peptide Cancer Vaccine Market Size by Pipeline
10.1.1 China Peptide Cancer Vaccine Revenue by Pipeline (2019-2030)
10.1.2 China Peptide Cancer Vaccine Sales by Pipeline (2019-2030)
10.1.3 China Peptide Cancer Vaccine Price by Pipeline (2019-2030)
10.2 China Peptide Cancer Vaccine Market Size by Application
10.2.1 China Peptide Cancer Vaccine Revenue by Application (2019-2030)
10.2.2 China Peptide Cancer Vaccine Sales by Application (2019-2030)
10.2.3 China Peptide Cancer Vaccine Price by Application (2019-2030)
11 ASIA (EXCLUDING CHINA)
11.1 Asia Peptide Cancer Vaccine Market Size by Pipeline
11.1.1 Asia Peptide Cancer Vaccine Revenue by Pipeline (2019-2030)
11.1.2 Asia Peptide Cancer Vaccine Sales by Pipeline (2019-2030)
11.1.3 Asia Peptide Cancer Vaccine Price by Pipeline (2019-2030)
11.2 Asia Peptide Cancer Vaccine Market Size by Application
11.2.1 Asia Peptide Cancer Vaccine Revenue by Application (2019-2030)
11.2.2 Asia Peptide Cancer Vaccine Sales by Application (2019-2030)
11.2.3 Asia Peptide Cancer Vaccine Price by Application (2019-2030)
11.3 Asia Peptide Cancer Vaccine Market Size by Country
11.3.1 Asia Peptide Cancer Vaccine Revenue Grow Rate by Country (2019 VS 2023 VS 2030)
11.3.2 Asia Peptide Cancer Vaccine Sales by Country (2019 VS 2023 VS 2030)
11.3.3 Asia Peptide Cancer Vaccine Price by Country (2019-2030)
11.3.4 Japan
11.3.5 South Korea
11.3.6 India
11.3.7 Australia
11.3.8 China Taiwan
11.3.9 Southeast Asia
12 MIDDLE EAST, AFRICA AND LATIN AMERICA
12.1 MEALA Peptide Cancer Vaccine Market Size by Pipeline
12.1.1 MEALA Peptide Cancer Vaccine Revenue by Pipeline (2019-2030)
12.1.2 MEALA Peptide Cancer Vaccine Sales by Pipeline (2019-2030)
12.1.3 MEALA Peptide Cancer Vaccine Price by Pipeline (2019-2030)
12.2 MEALA Peptide Cancer Vaccine Market Size by Application
12.2.1 MEALA Peptide Cancer Vaccine Revenue by Application (2019-2030)
12.2.2 MEALA Peptide Cancer Vaccine Sales by Application (2019-2030)
12.2.3 MEALA Peptide Cancer Vaccine Price by Application (2019-2030)
12.3 MEALA Peptide Cancer Vaccine Market Size by Country
12.3.1 MEALA Peptide Cancer Vaccine Revenue Grow Rate by Country (2019 VS 2023 VS 2030)
12.3.2 MEALA Peptide Cancer Vaccine Sales by Country (2019 VS 2023 VS 2030)
12.3.3 MEALA Peptide Cancer Vaccine Price by Country (2019-2030)
12.3.4 Mexico
12.3.5 Brazil
12.3.6 Israel
12.3.7 Argentina
12.3.8 Colombia
12.3.9 Turkey
12.3.10 Saudi Arabia
12.3.11 UAE
13 VALUE CHAIN AND SALES CHANNELS ANALYSIS
13.1 Peptide Cancer Vaccine Value Chain Analysis
13.1.1 Peptide Cancer Vaccine Key Raw Materials
13.1.2 Raw Materials Key Suppliers
13.1.3 Manufacturing Cost Structure
13.1.4 Peptide Cancer Vaccine Production Mode & Process
13.2 Peptide Cancer Vaccine Sales Channels Analysis
13.2.1 Direct Comparison with Distribution Share
13.2.2 Peptide Cancer Vaccine Distributors
13.2.3 Peptide Cancer Vaccine Customers
14 CONCLUDING INSIGHTS
15 APPENDIX
15.1 Reasons for Doing This Study
15.2 Research Methodology
15.3 Research Process
15.4 Authors List of This Report
15.5 Data Source
15.5.1 Secondary Sources
15.5.2 Primary Sources
15.6 Disclaimer
LIST OF TABLES
Table 1. Global Peptide Cancer Vaccine Market Size Growth Rate by Pipeline (US$ Million), 2019 VS 2023 VS 2030
Table 2. ITK-1 Major Manufacturers
Table 3. GRN-1201 Major Manufacturers
Table 4. TPIV200 Major Manufacturers
Table 5. TPIV110 Major Manufacturers
Table 6. UV1 Major Manufacturers
Table 7. Galinpepimut-S Major Manufacturers
Table 8. TARP 27-35 Major Manufacturers
Table 9. HER-Vaxx Major Manufacturers
Table 10. Vx-001 Major Manufacturers
Table 11. Others Major Manufacturers
Table 12. Global Peptide Cancer Vaccine Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
Table 13. Breast Cancer Major Manufacturers
Table 14. Lung Cancer Major Manufacturers
Table 15. Melanoma Major Manufacturers
Table 16. Prostate Cancer Major Manufacturers
Table 17. Others Major Manufacturers
Table 18. Peptide Cancer Vaccine Industry Trends
Table 19. Peptide Cancer Vaccine Industry Drivers
Table 20. Peptide Cancer Vaccine Industry Opportunities and Challenges
Table 21. Peptide Cancer Vaccine Industry Restraints
Table 22. Global Peptide Cancer Vaccine Revenue Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 23. Global Peptide Cancer Vaccine Revenue by Region (2019-2024) & (US$ Million)
Table 24. Global Peptide Cancer Vaccine Revenue by Region (2025-2030) & (US$ Million)
Table 25. Global Peptide Cancer Vaccine Revenue Market Share by Region (2019-2024)
Table 26. Global Peptide Cancer Vaccine Revenue Market Share by Region (2025-2030)
Table 27. Global Peptide Cancer Vaccine Sales Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (K Doses)
Table 28. Global Peptide Cancer Vaccine Sales by Region (2019-2024) & (K Doses)
Table 29. Global Peptide Cancer Vaccine Sales by Region (2025-2030) & (K Doses)
Table 30. Global Peptide Cancer Vaccine Sales Market Share by Region (2019-2024)
Table 31. Global Peptide Cancer Vaccine Sales Market Share by Region (2025-2030)
Table 32. Global Peptide Cancer Vaccine Revenue by Manufacturers (US$ Million) & (2019-2024)
Table 33. Global Peptide Cancer Vaccine Revenue Market Share by Manufacturers (2019-2024)
Table 34. Global Peptide Cancer Vaccine Sales by Manufacturers (US$ Million) & (2019-2024)
Table 35. Global Peptide Cancer Vaccine Sales Market Share by Manufacturers (2019-2024)
Table 36. Global Peptide Cancer Vaccine Sales Price (USD/Dose) of Manufacturers (2019-2024)
Table 37. Global Peptide Cancer Vaccine Key Manufacturers Ranking, 2022 VS 2023 VS 2024
Table 38. Global Peptide Cancer Vaccine Key Manufacturers Manufacturing Sites & Headquarters
Table 39. Global Peptide Cancer Vaccine Manufacturers, Product Type & Application
Table 40. Global Peptide Cancer Vaccine Manufacturers Commercialization Time
Table 41. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 42. Global Peptide Cancer Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2023)
Table 43. Global Peptide Cancer Vaccine Revenue by Pipeline 2019 VS 2023 VS 2030 (US$ Million)
Table 44. Global Peptide Cancer Vaccine Revenue by Pipeline (2019-2024) & (US$ Million)
Table 45. Global Peptide Cancer Vaccine Revenue by Pipeline (2025-2030) & (US$ Million)
Table 46. Global Peptide Cancer Vaccine Revenue Market Share by Pipeline (2019-2024)
Table 47. Global Peptide Cancer Vaccine Revenue Market Share by Pipeline (2025-2030)
Table 48. Global Peptide Cancer Vaccine Sales by Pipeline 2019 VS 2023 VS 2030 (K Doses)
Table 49. Global Peptide Cancer Vaccine Sales by Pipeline (2019-2024) & (K Doses)
Table 50. Global Peptide Cancer Vaccine Sales by Pipeline (2025-2030) & (K Doses)
Table 51. Global Peptide Cancer Vaccine Sales Market Share by Pipeline (2019-2024)
Table 52. Global Peptide Cancer Vaccine Sales Market Share by Pipeline (2025-2030)
Table 53. Global Peptide Cancer Vaccine Price by Pipeline (2019-2024) & (USD/Dose)
Table 54. Global Peptide Cancer Vaccine Price by Pipeline (2025-2030) & (USD/Dose)
Table 55. Global Peptide Cancer Vaccine Revenue by Application 2019 VS 2023 VS 2030 (US$ Million)
Table 56. Global Peptide Cancer Vaccine Revenue by Application (2019-2024) & (US$ Million)
Table 57. Global Peptide Cancer Vaccine Revenue by Application (2025-2030) & (US$ Million)
Table 58. Global Peptide Cancer Vaccine Revenue Market Share by Application (2019-2024)
Table 59. Global Peptide Cancer Vaccine Revenue Market Share by Application (2025-2030)
Table 60. Global Peptide Cancer Vaccine Sales by Application 2019 VS 2023 VS 2030 (K Doses)
Table 61. Global Peptide Cancer Vaccine Sales by Application (2019-2024) & (K Doses)
Table 62. Global Peptide Cancer Vaccine Sales by Application (2025-2030) & (K Doses)
Table 63. Global Peptide Cancer Vaccine Sales Market Share by Application (2019-2024)
Table 64. Global Peptide Cancer Vaccine Sales Market Share by Application (2025-2030)
Table 65. Global Peptide Cancer Vaccine Price by Application (2019-2024) & (USD/Dose)
Table 66. Global Peptide Cancer Vaccine Price by Application (2025-2030) & (USD/Dose)
Table 67. Boston Biomedical Company Information
Table 68. Boston Biomedical Business Overview
Table 69. Boston Biomedical Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 70. Boston Biomedical Peptide Cancer Vaccine Product Portfolio
Table 71. Boston Biomedical Recent Development
Table 72. Ultimovacs Company Information
Table 73. Ultimovacs Business Overview
Table 74. Ultimovacs Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 75. Ultimovacs Peptide Cancer Vaccine Product Portfolio
Table 76. Ultimovacs Recent Development
Table 77. BrightPath Biotherapeutics Company Information
Table 78. BrightPath Biotherapeutics Business Overview
Table 79. BrightPath Biotherapeutics Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 80. BrightPath Biotherapeutics Peptide Cancer Vaccine Product Portfolio
Table 81. BrightPath Biotherapeutics Recent Development
Table 82. TapImmune Company Information
Table 83. TapImmune Business Overview
Table 84. TapImmune Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 85. TapImmune Peptide Cancer Vaccine Product Portfolio
Table 86. TapImmune Recent Development
Table 87. Immatics Company Information
Table 88. Immatics Business Overview
Table 89. Immatics Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 90. Immatics Peptide Cancer Vaccine Product Portfolio
Table 91. Immatics Recent Development
Table 92. Sellas Company Information
Table 93. Sellas Business Overview
Table 94. Sellas Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 95. Sellas Peptide Cancer Vaccine Product Portfolio
Table 96. Sellas Recent Development
Table 97. Imugene Company Information
Table 98. Imugene Business Overview
Table 99. Imugene Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 100. Imugene Peptide Cancer Vaccine Product Portfolio
Table 101. Imugene Recent Development
Table 102. VAXON Biotech Company Information
Table 103. VAXON Biotech Business Overview
Table 104. VAXON Biotech Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 105. VAXON Biotech Peptide Cancer Vaccine Product Portfolio
Table 106. VAXON Biotech Recent Development
Table 107. Generex Biotechnology Company Information
Table 108. Generex Biotechnology Business Overview
Table 109. Generex Biotechnology Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 110. Generex Biotechnology Peptide Cancer Vaccine Product Portfolio
Table 111. Generex Biotechnology Recent Development
Table 112. ISA Pharmaceuticals Company Information
Table 113. ISA Pharmaceuticals Business Overview
Table 114. ISA Pharmaceuticals Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 115. ISA Pharmaceuticals Peptide Cancer Vaccine Product Portfolio
Table 116. ISA Pharmaceuticals Recent Development
Table 117. OncoTherapy Science Company Information
Table 118. OncoTherapy Science Business Overview
Table 119. OncoTherapy Science Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 120. OncoTherapy Science Peptide Cancer Vaccine Product Portfolio
Table 121. OncoTherapy Science Recent Development
Table 122. North America Peptide Cancer Vaccine Revenue by Pipeline (2019-2024) & (US$ Million)
Table 123. North America Peptide Cancer Vaccine Revenue by Pipeline (2025-2030) & (US$ Million)
Table 124. North America Peptide Cancer Vaccine Sales by Pipeline (2019-2024) & (K Doses)
Table 125. North America Peptide Cancer Vaccine Sales by Pipeline (2025-2030) & (K Doses)
Table 126. North America Peptide Cancer Vaccine Sales Price by Pipeline (2019-2024) & (USD/Dose)
Table 127. North America Peptide Cancer Vaccine Sales Price by Pipeline (2025-2030) & (USD/Dose)
Table 128. North America Peptide Cancer Vaccine Revenue by Application (2019-2024) & (US$ Million)
Table 129. North America Peptide Cancer Vaccine Revenue by Application (2025-2030) & (US$ Million)
Table 130. North America Peptide Cancer Vaccine Sales by Application (2019-2024) & (K Doses)
Table 131. North America Peptide Cancer Vaccine Sales by Application (2025-2030) & (K Doses)
Table 132. North America Peptide Cancer Vaccine Sales Price by Application (2019-2024) & (USD/Dose)
Table 133. North America Peptide Cancer Vaccine Sales Price by Application (2025-2030) & (USD/Dose)
Table 134. North America Peptide Cancer Vaccine Revenue Grow Rate by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 135. North America Peptide Cancer Vaccine Revenue Grow Rate by Country (2019-2024) & (US$ Million)
Table 136. North America Peptide Cancer Vaccine Revenue Grow Rate by Country (2025-2030) & (US$ Million)
Table 137. North America Peptide Cancer Vaccine Sales by Country (2019 VS 2023 VS 2030) & (K Doses)
Table 138. North America Peptide Cancer Vaccine Sales by Country (2019-2024) & (K Doses)
Table 139. North America Peptide Cancer Vaccine Sales by Country (2025-2030) & (K Doses)
Table 140. North America Peptide Cancer Vaccine Sales Price by Country (2019-2024) & (USD/Dose)
Table 141. North America Peptide Cancer Vaccine Sales Price by Country (2025-2030) & (USD/Dose)
Table 142. US Peptide Cancer Vaccine Revenue (2019-2030) & (US$ Million)
Table 143. Canada Peptide Cancer Vaccine Revenue (2019-2030) & (US$ Million)
Table 144. Europe Peptide Cancer Vaccine Revenue by Pipeline (2019-2024) & (US$ Million)
Table 145. Europe Peptide Cancer Vaccine Revenue by Pipeline (2025-2030) & (US$ Million)
Table 146. Europe Peptide Cancer Vaccine Sales by Pipeline (2019-2024) & (K Doses)
Table 147. Europe Peptide Cancer Vaccine Sales by Pipeline (2025-2030) & (K Doses)
Table 148. Europe Peptide Cancer Vaccine Sales Price by Pipeline (2019-2024) & (USD/Dose)
Table 149. Europe Peptide Cancer Vaccine Sales Price by Pipeline (2025-2030) & (USD/Dose)
Table 150. Europe Peptide Cancer Vaccine Revenue by Application (2019-2024) & (US$ Million)
Table 151. Europe Peptide Cancer Vaccine Revenue by Application (2025-2030) & (US$ Million)
Table 152. Europe Peptide Cancer Vaccine Sales by Application (2019-2024) & (K Doses)
Table 153. Europe Peptide Cancer Vaccine Sales by Application (2025-2030) & (K Doses)
Table 154. Europe Peptide Cancer Vaccine Sales Price by Application (2019-2024) & (USD/Dose)
Table 155. Europe Peptide Cancer Vaccine Sales Price by Application (2025-2030) & (USD/Dose)
Table 156. Europe Peptide Cancer Vaccine Revenue Grow Rate by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 157. Europe Peptide Cancer Vaccine Revenue Grow Rate by Country (2019-2024) & (US$ Million)
Table 158. Europe Peptide Cancer Vaccine Revenue Grow Rate by Country (2025-2030) & (US$ Million)
Table 159. Europe Peptide Cancer Vaccine Sales by Country (2019 VS 2023 VS 2030) & (K Doses)
Table 160. Europe Peptide Cancer Vaccine Sales by Country (2019-2024) & (K Doses)
Table 161. Europe Peptide Cancer Vaccine Sales by Country (2025-2030) & (K Doses)
Table 162. Europe Peptide Cancer Vaccine Sales Price by Country (2019-2024) & (USD/Dose)
Table 163. Europe Peptide Cancer Vaccine Sales Price by Country (2025-2030) & (USD/Dose)
Table 164. Germany Peptide Cancer Vaccine Revenue (2019-2030) & (US$ Million)
Table 165. France Peptide Cancer Vaccine Revenue (2019-2030) & (US$ Million)
Table 166. Peptide Cancer Vaccine Revenue (2019-2030) & (US$ Million)
Table 167. Peptide Cancer Vaccine Revenue (2019-2030) & (US$ Million)
Table 168. Peptide Cancer Vaccine Revenue (2019-2030) & (US$ Million)
Table 169. China Peptide Cancer Vaccine Revenue by Pipeline (2019-2024) & (US$ Million)
Table 170. China Peptide Cancer Vaccine Revenue by Pipeline (2025-2030) & (US$ Million)
Table 171. China Peptide Cancer Vaccine Sales by Pipeline (2019-2024) & (K Doses)
Table 172. China Peptide Cancer Vaccine Sales by Pipeline (2025-2030) & (K Doses)
Table 173. China Peptide Cancer Vaccine Sales Price by Pipeline (2019-2024) & (USD/Dose)
Table 174. China Peptide Cancer Vaccine Sales Price by Pipeline (2025-2030) & (USD/Dose)
Table 175. China Peptide Cancer Vaccine Revenue by Application (2019-2024) & (US$ Million)
Table 176. China Peptide Cancer Vaccine Revenue by Application (2025-2030) & (US$ Million)
Table 177. China Peptide Cancer Vaccine Sales by Application (2019-2024) & (K Doses)
Table 178. China Peptide Cancer Vaccine Sales by Application (2025-2030) & (K Doses)
Table 179. China Peptide Cancer Vaccine Sales Price by Application (2019-2024) & (USD/Dose)
Table 180. China Peptide Cancer Vaccine Sales Price by Application (2025-2030) & (USD/Dose)
Table 181. Asia Peptide Cancer Vaccine Revenue by Pipeline (2019-2024) & (US$ Million)
Table 182. Asia Peptide Cancer Vaccine Revenue by Pipeline (2025-2030) & (US$ Million)
Table 183. Asia Peptide Cancer Vaccine Sales by Pipeline (2019-2024) & (K Doses)
Table 184. Asia Peptide Cancer Vaccine Sales by Pipeline (2025-2030) & (K Doses)
Table 185. Asia Peptide Cancer Vaccine Sales Price by Pipeline (2019-2024) & (USD/Dose)
Table 186. Asia Peptide Cancer Vaccine Sales Price by Pipeline (2025-2030) & (USD/Dose)
Table 187. Asia Peptide Cancer Vaccine Revenue by Application (2019-2024) & (US$ Million)
Table 188. Asia Peptide Cancer Vaccine Revenue by Application (2025-2030) & (US$ Million)
Table 189. Asia Peptide Cancer Vaccine Sales by Application (2019-2024) & (K Doses)
Table 190. Asia Peptide Cancer Vaccine Sales by Application (2025-2030) & (K Doses)
Table 191. Asia Peptide Cancer Vaccine Sales Price by Application (2019-2024) & (USD/Dose)
Table 192. Asia Peptide Cancer Vaccine Sales Price by Application (2025-2030) & (USD/Dose)
Table 193. Asia Peptide Cancer Vaccine Revenue Grow Rate by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 194. Asia Peptide Cancer Vaccine Revenue Grow Rate by Country (2019-2024) & (US$ Million)
Table 195. Asia Peptide Cancer Vaccine Revenue Grow Rate by Country (2025-2030) & (US$ Million)
Table 196. Asia Peptide Cancer Vaccine Sales by Country (2019 VS 2023 VS 2030) & (K Doses)
Table 197. Asia Peptide Cancer Vaccine Sales by Country (2019-2024) & (K Doses)
Table 198. Asia Peptide Cancer Vaccine Sales by Country (2025-2030) & (K Doses)
Table 199. Asia Peptide Cancer Vaccine Sales Price by Country (2019-2024) & (USD/Dose)
Table 200. Asia Peptide Cancer Vaccine Sales Price by Country (2025-2030) & (USD/Dose)
Table 201. Japan Peptide Cancer Vaccine Revenue (2019-2030) & (US$ Million)
Table 202. South Korea Peptide Cancer Vaccine Revenue (2019-2030) & (US$ Million)
Table 203. Peptide Cancer Vaccine Revenue (2019-2030) & (US$ Million)
Table 204. Peptide Cancer Vaccine Revenue (2019-2030) & (US$ Million)
Table 205. Peptide Cancer Vaccine Revenue (2019-2030) & (US$ Million)
Table 206. Peptide Cancer Vaccine Revenue (2019-2030) & (US$ Million)
Table 207. Peptide Cancer Vaccine Revenue (2019-2030) & (US$ Million)
Table 208. Peptide Cancer Vaccine Revenue (2019-2030) & (US$ Million)
Table 209. MEALA Peptide Cancer Vaccine Revenue by Pipeline (2019-2024) & (US$ Million)
Table 210. MEALA Peptide Cancer Vaccine Revenue by Pipeline (2025-2030) & (US$ Million)
Table 211. MEALA Peptide Cancer Vaccine Sales by Pipeline (2019-2024) & (K Doses)
Table 212. MEALA Peptide Cancer Vaccine Sales by Pipeline (2025-2030) & (K Doses)
Table 213. MEALA Peptide Cancer Vaccine Sales Price by Pipeline (2019-2024) & (USD/Dose)
Table 214. MEALA Peptide Cancer Vaccine Sales Price by Pipeline (2025-2030) & (USD/Dose)
Table 215. MEALA Peptide Cancer Vaccine Revenue by Application (2019-2024) & (US$ Million)
Table 216. MEALA Peptide Cancer Vaccine Revenue by Application (2025-2030) & (US$ Million)
Table 217. MEALA Peptide Cancer Vaccine Sales by Application (2019-2024) & (K Doses)
Table 218. MEALA Peptide Cancer Vaccine Sales by Application (2025-2030) & (K Doses)
Table 219. ME
Table 1. Global Peptide Cancer Vaccine Market Size Growth Rate by Pipeline (US$ Million), 2019 VS 2023 VS 2030
Table 2. ITK-1 Major Manufacturers
Table 3. GRN-1201 Major Manufacturers
Table 4. TPIV200 Major Manufacturers
Table 5. TPIV110 Major Manufacturers
Table 6. UV1 Major Manufacturers
Table 7. Galinpepimut-S Major Manufacturers
Table 8. TARP 27-35 Major Manufacturers
Table 9. HER-Vaxx Major Manufacturers
Table 10. Vx-001 Major Manufacturers
Table 11. Others Major Manufacturers
Table 12. Global Peptide Cancer Vaccine Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
Table 13. Breast Cancer Major Manufacturers
Table 14. Lung Cancer Major Manufacturers
Table 15. Melanoma Major Manufacturers
Table 16. Prostate Cancer Major Manufacturers
Table 17. Others Major Manufacturers
Table 18. Peptide Cancer Vaccine Industry Trends
Table 19. Peptide Cancer Vaccine Industry Drivers
Table 20. Peptide Cancer Vaccine Industry Opportunities and Challenges
Table 21. Peptide Cancer Vaccine Industry Restraints
Table 22. Global Peptide Cancer Vaccine Revenue Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 23. Global Peptide Cancer Vaccine Revenue by Region (2019-2024) & (US$ Million)
Table 24. Global Peptide Cancer Vaccine Revenue by Region (2025-2030) & (US$ Million)
Table 25. Global Peptide Cancer Vaccine Revenue Market Share by Region (2019-2024)
Table 26. Global Peptide Cancer Vaccine Revenue Market Share by Region (2025-2030)
Table 27. Global Peptide Cancer Vaccine Sales Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (K Doses)
Table 28. Global Peptide Cancer Vaccine Sales by Region (2019-2024) & (K Doses)
Table 29. Global Peptide Cancer Vaccine Sales by Region (2025-2030) & (K Doses)
Table 30. Global Peptide Cancer Vaccine Sales Market Share by Region (2019-2024)
Table 31. Global Peptide Cancer Vaccine Sales Market Share by Region (2025-2030)
Table 32. Global Peptide Cancer Vaccine Revenue by Manufacturers (US$ Million) & (2019-2024)
Table 33. Global Peptide Cancer Vaccine Revenue Market Share by Manufacturers (2019-2024)
Table 34. Global Peptide Cancer Vaccine Sales by Manufacturers (US$ Million) & (2019-2024)
Table 35. Global Peptide Cancer Vaccine Sales Market Share by Manufacturers (2019-2024)
Table 36. Global Peptide Cancer Vaccine Sales Price (USD/Dose) of Manufacturers (2019-2024)
Table 37. Global Peptide Cancer Vaccine Key Manufacturers Ranking, 2022 VS 2023 VS 2024
Table 38. Global Peptide Cancer Vaccine Key Manufacturers Manufacturing Sites & Headquarters
Table 39. Global Peptide Cancer Vaccine Manufacturers, Product Type & Application
Table 40. Global Peptide Cancer Vaccine Manufacturers Commercialization Time
Table 41. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 42. Global Peptide Cancer Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2023)
Table 43. Global Peptide Cancer Vaccine Revenue by Pipeline 2019 VS 2023 VS 2030 (US$ Million)
Table 44. Global Peptide Cancer Vaccine Revenue by Pipeline (2019-2024) & (US$ Million)
Table 45. Global Peptide Cancer Vaccine Revenue by Pipeline (2025-2030) & (US$ Million)
Table 46. Global Peptide Cancer Vaccine Revenue Market Share by Pipeline (2019-2024)
Table 47. Global Peptide Cancer Vaccine Revenue Market Share by Pipeline (2025-2030)
Table 48. Global Peptide Cancer Vaccine Sales by Pipeline 2019 VS 2023 VS 2030 (K Doses)
Table 49. Global Peptide Cancer Vaccine Sales by Pipeline (2019-2024) & (K Doses)
Table 50. Global Peptide Cancer Vaccine Sales by Pipeline (2025-2030) & (K Doses)
Table 51. Global Peptide Cancer Vaccine Sales Market Share by Pipeline (2019-2024)
Table 52. Global Peptide Cancer Vaccine Sales Market Share by Pipeline (2025-2030)
Table 53. Global Peptide Cancer Vaccine Price by Pipeline (2019-2024) & (USD/Dose)
Table 54. Global Peptide Cancer Vaccine Price by Pipeline (2025-2030) & (USD/Dose)
Table 55. Global Peptide Cancer Vaccine Revenue by Application 2019 VS 2023 VS 2030 (US$ Million)
Table 56. Global Peptide Cancer Vaccine Revenue by Application (2019-2024) & (US$ Million)
Table 57. Global Peptide Cancer Vaccine Revenue by Application (2025-2030) & (US$ Million)
Table 58. Global Peptide Cancer Vaccine Revenue Market Share by Application (2019-2024)
Table 59. Global Peptide Cancer Vaccine Revenue Market Share by Application (2025-2030)
Table 60. Global Peptide Cancer Vaccine Sales by Application 2019 VS 2023 VS 2030 (K Doses)
Table 61. Global Peptide Cancer Vaccine Sales by Application (2019-2024) & (K Doses)
Table 62. Global Peptide Cancer Vaccine Sales by Application (2025-2030) & (K Doses)
Table 63. Global Peptide Cancer Vaccine Sales Market Share by Application (2019-2024)
Table 64. Global Peptide Cancer Vaccine Sales Market Share by Application (2025-2030)
Table 65. Global Peptide Cancer Vaccine Price by Application (2019-2024) & (USD/Dose)
Table 66. Global Peptide Cancer Vaccine Price by Application (2025-2030) & (USD/Dose)
Table 67. Boston Biomedical Company Information
Table 68. Boston Biomedical Business Overview
Table 69. Boston Biomedical Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 70. Boston Biomedical Peptide Cancer Vaccine Product Portfolio
Table 71. Boston Biomedical Recent Development
Table 72. Ultimovacs Company Information
Table 73. Ultimovacs Business Overview
Table 74. Ultimovacs Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 75. Ultimovacs Peptide Cancer Vaccine Product Portfolio
Table 76. Ultimovacs Recent Development
Table 77. BrightPath Biotherapeutics Company Information
Table 78. BrightPath Biotherapeutics Business Overview
Table 79. BrightPath Biotherapeutics Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 80. BrightPath Biotherapeutics Peptide Cancer Vaccine Product Portfolio
Table 81. BrightPath Biotherapeutics Recent Development
Table 82. TapImmune Company Information
Table 83. TapImmune Business Overview
Table 84. TapImmune Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 85. TapImmune Peptide Cancer Vaccine Product Portfolio
Table 86. TapImmune Recent Development
Table 87. Immatics Company Information
Table 88. Immatics Business Overview
Table 89. Immatics Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 90. Immatics Peptide Cancer Vaccine Product Portfolio
Table 91. Immatics Recent Development
Table 92. Sellas Company Information
Table 93. Sellas Business Overview
Table 94. Sellas Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 95. Sellas Peptide Cancer Vaccine Product Portfolio
Table 96. Sellas Recent Development
Table 97. Imugene Company Information
Table 98. Imugene Business Overview
Table 99. Imugene Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 100. Imugene Peptide Cancer Vaccine Product Portfolio
Table 101. Imugene Recent Development
Table 102. VAXON Biotech Company Information
Table 103. VAXON Biotech Business Overview
Table 104. VAXON Biotech Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 105. VAXON Biotech Peptide Cancer Vaccine Product Portfolio
Table 106. VAXON Biotech Recent Development
Table 107. Generex Biotechnology Company Information
Table 108. Generex Biotechnology Business Overview
Table 109. Generex Biotechnology Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 110. Generex Biotechnology Peptide Cancer Vaccine Product Portfolio
Table 111. Generex Biotechnology Recent Development
Table 112. ISA Pharmaceuticals Company Information
Table 113. ISA Pharmaceuticals Business Overview
Table 114. ISA Pharmaceuticals Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 115. ISA Pharmaceuticals Peptide Cancer Vaccine Product Portfolio
Table 116. ISA Pharmaceuticals Recent Development
Table 117. OncoTherapy Science Company Information
Table 118. OncoTherapy Science Business Overview
Table 119. OncoTherapy Science Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 120. OncoTherapy Science Peptide Cancer Vaccine Product Portfolio
Table 121. OncoTherapy Science Recent Development
Table 122. North America Peptide Cancer Vaccine Revenue by Pipeline (2019-2024) & (US$ Million)
Table 123. North America Peptide Cancer Vaccine Revenue by Pipeline (2025-2030) & (US$ Million)
Table 124. North America Peptide Cancer Vaccine Sales by Pipeline (2019-2024) & (K Doses)
Table 125. North America Peptide Cancer Vaccine Sales by Pipeline (2025-2030) & (K Doses)
Table 126. North America Peptide Cancer Vaccine Sales Price by Pipeline (2019-2024) & (USD/Dose)
Table 127. North America Peptide Cancer Vaccine Sales Price by Pipeline (2025-2030) & (USD/Dose)
Table 128. North America Peptide Cancer Vaccine Revenue by Application (2019-2024) & (US$ Million)
Table 129. North America Peptide Cancer Vaccine Revenue by Application (2025-2030) & (US$ Million)
Table 130. North America Peptide Cancer Vaccine Sales by Application (2019-2024) & (K Doses)
Table 131. North America Peptide Cancer Vaccine Sales by Application (2025-2030) & (K Doses)
Table 132. North America Peptide Cancer Vaccine Sales Price by Application (2019-2024) & (USD/Dose)
Table 133. North America Peptide Cancer Vaccine Sales Price by Application (2025-2030) & (USD/Dose)
Table 134. North America Peptide Cancer Vaccine Revenue Grow Rate by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 135. North America Peptide Cancer Vaccine Revenue Grow Rate by Country (2019-2024) & (US$ Million)
Table 136. North America Peptide Cancer Vaccine Revenue Grow Rate by Country (2025-2030) & (US$ Million)
Table 137. North America Peptide Cancer Vaccine Sales by Country (2019 VS 2023 VS 2030) & (K Doses)
Table 138. North America Peptide Cancer Vaccine Sales by Country (2019-2024) & (K Doses)
Table 139. North America Peptide Cancer Vaccine Sales by Country (2025-2030) & (K Doses)
Table 140. North America Peptide Cancer Vaccine Sales Price by Country (2019-2024) & (USD/Dose)
Table 141. North America Peptide Cancer Vaccine Sales Price by Country (2025-2030) & (USD/Dose)
Table 142. US Peptide Cancer Vaccine Revenue (2019-2030) & (US$ Million)
Table 143. Canada Peptide Cancer Vaccine Revenue (2019-2030) & (US$ Million)
Table 144. Europe Peptide Cancer Vaccine Revenue by Pipeline (2019-2024) & (US$ Million)
Table 145. Europe Peptide Cancer Vaccine Revenue by Pipeline (2025-2030) & (US$ Million)
Table 146. Europe Peptide Cancer Vaccine Sales by Pipeline (2019-2024) & (K Doses)
Table 147. Europe Peptide Cancer Vaccine Sales by Pipeline (2025-2030) & (K Doses)
Table 148. Europe Peptide Cancer Vaccine Sales Price by Pipeline (2019-2024) & (USD/Dose)
Table 149. Europe Peptide Cancer Vaccine Sales Price by Pipeline (2025-2030) & (USD/Dose)
Table 150. Europe Peptide Cancer Vaccine Revenue by Application (2019-2024) & (US$ Million)
Table 151. Europe Peptide Cancer Vaccine Revenue by Application (2025-2030) & (US$ Million)
Table 152. Europe Peptide Cancer Vaccine Sales by Application (2019-2024) & (K Doses)
Table 153. Europe Peptide Cancer Vaccine Sales by Application (2025-2030) & (K Doses)
Table 154. Europe Peptide Cancer Vaccine Sales Price by Application (2019-2024) & (USD/Dose)
Table 155. Europe Peptide Cancer Vaccine Sales Price by Application (2025-2030) & (USD/Dose)
Table 156. Europe Peptide Cancer Vaccine Revenue Grow Rate by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 157. Europe Peptide Cancer Vaccine Revenue Grow Rate by Country (2019-2024) & (US$ Million)
Table 158. Europe Peptide Cancer Vaccine Revenue Grow Rate by Country (2025-2030) & (US$ Million)
Table 159. Europe Peptide Cancer Vaccine Sales by Country (2019 VS 2023 VS 2030) & (K Doses)
Table 160. Europe Peptide Cancer Vaccine Sales by Country (2019-2024) & (K Doses)
Table 161. Europe Peptide Cancer Vaccine Sales by Country (2025-2030) & (K Doses)
Table 162. Europe Peptide Cancer Vaccine Sales Price by Country (2019-2024) & (USD/Dose)
Table 163. Europe Peptide Cancer Vaccine Sales Price by Country (2025-2030) & (USD/Dose)
Table 164. Germany Peptide Cancer Vaccine Revenue (2019-2030) & (US$ Million)
Table 165. France Peptide Cancer Vaccine Revenue (2019-2030) & (US$ Million)
Table 166. Peptide Cancer Vaccine Revenue (2019-2030) & (US$ Million)
Table 167. Peptide Cancer Vaccine Revenue (2019-2030) & (US$ Million)
Table 168. Peptide Cancer Vaccine Revenue (2019-2030) & (US$ Million)
Table 169. China Peptide Cancer Vaccine Revenue by Pipeline (2019-2024) & (US$ Million)
Table 170. China Peptide Cancer Vaccine Revenue by Pipeline (2025-2030) & (US$ Million)
Table 171. China Peptide Cancer Vaccine Sales by Pipeline (2019-2024) & (K Doses)
Table 172. China Peptide Cancer Vaccine Sales by Pipeline (2025-2030) & (K Doses)
Table 173. China Peptide Cancer Vaccine Sales Price by Pipeline (2019-2024) & (USD/Dose)
Table 174. China Peptide Cancer Vaccine Sales Price by Pipeline (2025-2030) & (USD/Dose)
Table 175. China Peptide Cancer Vaccine Revenue by Application (2019-2024) & (US$ Million)
Table 176. China Peptide Cancer Vaccine Revenue by Application (2025-2030) & (US$ Million)
Table 177. China Peptide Cancer Vaccine Sales by Application (2019-2024) & (K Doses)
Table 178. China Peptide Cancer Vaccine Sales by Application (2025-2030) & (K Doses)
Table 179. China Peptide Cancer Vaccine Sales Price by Application (2019-2024) & (USD/Dose)
Table 180. China Peptide Cancer Vaccine Sales Price by Application (2025-2030) & (USD/Dose)
Table 181. Asia Peptide Cancer Vaccine Revenue by Pipeline (2019-2024) & (US$ Million)
Table 182. Asia Peptide Cancer Vaccine Revenue by Pipeline (2025-2030) & (US$ Million)
Table 183. Asia Peptide Cancer Vaccine Sales by Pipeline (2019-2024) & (K Doses)
Table 184. Asia Peptide Cancer Vaccine Sales by Pipeline (2025-2030) & (K Doses)
Table 185. Asia Peptide Cancer Vaccine Sales Price by Pipeline (2019-2024) & (USD/Dose)
Table 186. Asia Peptide Cancer Vaccine Sales Price by Pipeline (2025-2030) & (USD/Dose)
Table 187. Asia Peptide Cancer Vaccine Revenue by Application (2019-2024) & (US$ Million)
Table 188. Asia Peptide Cancer Vaccine Revenue by Application (2025-2030) & (US$ Million)
Table 189. Asia Peptide Cancer Vaccine Sales by Application (2019-2024) & (K Doses)
Table 190. Asia Peptide Cancer Vaccine Sales by Application (2025-2030) & (K Doses)
Table 191. Asia Peptide Cancer Vaccine Sales Price by Application (2019-2024) & (USD/Dose)
Table 192. Asia Peptide Cancer Vaccine Sales Price by Application (2025-2030) & (USD/Dose)
Table 193. Asia Peptide Cancer Vaccine Revenue Grow Rate by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 194. Asia Peptide Cancer Vaccine Revenue Grow Rate by Country (2019-2024) & (US$ Million)
Table 195. Asia Peptide Cancer Vaccine Revenue Grow Rate by Country (2025-2030) & (US$ Million)
Table 196. Asia Peptide Cancer Vaccine Sales by Country (2019 VS 2023 VS 2030) & (K Doses)
Table 197. Asia Peptide Cancer Vaccine Sales by Country (2019-2024) & (K Doses)
Table 198. Asia Peptide Cancer Vaccine Sales by Country (2025-2030) & (K Doses)
Table 199. Asia Peptide Cancer Vaccine Sales Price by Country (2019-2024) & (USD/Dose)
Table 200. Asia Peptide Cancer Vaccine Sales Price by Country (2025-2030) & (USD/Dose)
Table 201. Japan Peptide Cancer Vaccine Revenue (2019-2030) & (US$ Million)
Table 202. South Korea Peptide Cancer Vaccine Revenue (2019-2030) & (US$ Million)
Table 203. Peptide Cancer Vaccine Revenue (2019-2030) & (US$ Million)
Table 204. Peptide Cancer Vaccine Revenue (2019-2030) & (US$ Million)
Table 205. Peptide Cancer Vaccine Revenue (2019-2030) & (US$ Million)
Table 206. Peptide Cancer Vaccine Revenue (2019-2030) & (US$ Million)
Table 207. Peptide Cancer Vaccine Revenue (2019-2030) & (US$ Million)
Table 208. Peptide Cancer Vaccine Revenue (2019-2030) & (US$ Million)
Table 209. MEALA Peptide Cancer Vaccine Revenue by Pipeline (2019-2024) & (US$ Million)
Table 210. MEALA Peptide Cancer Vaccine Revenue by Pipeline (2025-2030) & (US$ Million)
Table 211. MEALA Peptide Cancer Vaccine Sales by Pipeline (2019-2024) & (K Doses)
Table 212. MEALA Peptide Cancer Vaccine Sales by Pipeline (2025-2030) & (K Doses)
Table 213. MEALA Peptide Cancer Vaccine Sales Price by Pipeline (2019-2024) & (USD/Dose)
Table 214. MEALA Peptide Cancer Vaccine Sales Price by Pipeline (2025-2030) & (USD/Dose)
Table 215. MEALA Peptide Cancer Vaccine Revenue by Application (2019-2024) & (US$ Million)
Table 216. MEALA Peptide Cancer Vaccine Revenue by Application (2025-2030) & (US$ Million)
Table 217. MEALA Peptide Cancer Vaccine Sales by Application (2019-2024) & (K Doses)
Table 218. MEALA Peptide Cancer Vaccine Sales by Application (2025-2030) & (K Doses)
Table 219. ME
